5,118 reports of this reaction
4.7% of all GLATIRAMER ACETATE reports
#1 most reported adverse reaction
MULTIPLE SCLEROSIS RELAPSE is the #1 most commonly reported adverse reaction for GLATIRAMER ACETATE, manufactured by Teva Neuroscience, Inc.. There are 5,118 FDA adverse event reports linking GLATIRAMER ACETATE to MULTIPLE SCLEROSIS RELAPSE. This represents approximately 4.7% of all 108,384 adverse event reports for this drug.
Patients taking GLATIRAMER ACETATE who experience multiple sclerosis relapse should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MULTIPLE SCLEROSIS RELAPSE is moderately reported among GLATIRAMER ACETATE users, representing a notable but not dominant share of adverse events.
In addition to multiple sclerosis relapse, the following adverse reactions have been reported for GLATIRAMER ACETATE:
The following drugs have also been linked to multiple sclerosis relapse in FDA adverse event reports:
MULTIPLE SCLEROSIS RELAPSE has been reported as an adverse event in 5,118 FDA reports for GLATIRAMER ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MULTIPLE SCLEROSIS RELAPSE accounts for approximately 4.7% of all adverse event reports for GLATIRAMER ACETATE, making it one of the most commonly reported side effect.
If you experience multiple sclerosis relapse while taking GLATIRAMER ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.